About Clear Intradermal Technologies, Inc.
Clear Intradermal Technologies, Inc., a Delaware Corporation, was founded in 2013 by Dr. James W. Winkelman and Martin E. Schmieg. The Company’s mission is to design, develop and market the first effective, painless, single treatment tattoo ERASER® System – approaching 100% particle removal from the skin while safely avoiding current potential laser removal side-effects of scaring, skin color bleaching, shadow tattoos or absorption by the body of harmful mineral or chemical elements.
Nye is a C-level executive with management and marketing expertise in emerging healthcare companies. His previous experience includes leading ZELTIQ Aesthetics through a private funding round and IPO. He’s served in executive positions at the following companies: Angel Medical Systems, Inc., Atlantic Therapeutics, R2 Technologies, REVA Medical, Systagenix, Critikon, Inc., and A Company Orthodontics.
His early professional experience includes marketing roles at The Gillette Company, Reebok, LA Gear and President and COO of Voit Sports. Nye is a graduate of Dartmouth College and has an MBA from Dartmouth’s Amos Tuck School of Business.
Martin E. Schmieg,
"C" level executive since 1992 leading startup and development stage companies Cytometrics, Inc., Advanced Bionics Corporation, SIRNA Therapeutics, Inc., lsolagen, Inc., Freedom-2, Inc., now Pharmacyte, Inc. and NeoStem, Inc. Early career experience with Boekel Scientific, Inc. and EM Diagnostic Systems, Inc., a division of E. Merck. Martin is a CPA and is also the founder and managing partner of Soar Ventures, a venture capital and strategic advisory firm.
James W. Winkelman, M.D.,
Chief Scientific Officer
Professor Emeritus of Pathology at Harvard Medical School. Formerly, Director of Clinical Laboratories and Vice President of Brigham and Women’s Hospital. Founder of Cytometrics, Inc., Continuous Monitoring Calibration Systems, LLC, and Cell Imaging Systems, LLC. Dr. Winkelman, an AOA graduate from John’s Hopkins Medical School, has authored more than 160 peer reviewed scientific publications and 13 issued U.S. Patents. The Roche COBAS M-511 hematology system is based upon several of these enabling patents.
Richard Goldfarb, M.D.,
Chief Medical Officer
Dr. Goldfarb is a highly sought-after surgeon, speaker, and well-known leader in the Cosmetic, Laser, Aesthetic, and Regenerative Medicine sectors. As a Medical Director for Selphyl, Viora Laser, and Silhouette Lift, he has trained physicians worldwide. He has worked to prepare products for market including developing initial product trials as well as conducting FDA approval trials for the first Thread for facial skin lifting. He is a fellow of the American Society of Laser Medicine & Surgery and co-founder of the American Society of Cosmetic Physicians and Surgeons. He received his MD from University of Chicago, trained in Telesurgery at Yale University, and completed his plastic surgery training at the University of Pennsylvania.